IGEA Pharma N.V.
- ISIN: NL0012768675
- Land: Netherlands
Nachricht vom 25.11.2021 | 23:10
IGEA Pharma N.V.: GBC AG PUBLISHES INITIAL EQUITY RESEARCH REPORT WITH BUY RECOMMENDATION AND PRICE TARGET OF EUR 1.05
IGEA Pharma N.V. / Key word(s): Research Update/Research Update
GBC AG PUBLISHES INITIAL EQUITY RESEARCH REPORT WITH BUY RECOMMENDATION AND PRICE TARGET OF EUR 1.05
Hoofddorp, the Netherlands, 25 November 2021. IGEA Pharma N.V. (SIX: IGPH) receives an analyst vote. On Monday 22nd the research house GBC AG (www.gbc-ag.de/) publishes its first coverage equity research on the Company and from now on, GBC analysts Matthias Greiffenbergerand Felix Haugg will cover the further development of Igea Pharma NV with continuous assessment.
In their study, GBC highlights how "The CBD market is growing strongly and with a focus on quality leadership and pure extraction" further stating that "IGEA Pharma's new business model should be able to occupy an attractive niche market positioning the company at the highest quality level with CBD from CO2 extraction".
In GBC's view "In the long term, significantly higher prices can probably be achieved, provided that their own brand is established" and the analyst comment that "In addition to the declared goal of becoming the quality leader, the company also plans to become the cost leader. and therefore, very high margins should be possible".
Based on the valuation model, GBC has determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.
The full GBC study is available for download at www.igeapharma.nl
IGEA is listed on the SIX Swiss Exchange (ticker IGPH) and is headquartered in Hoofddorp, the Netherlands. Find out more at www.igeapharma.nl
End of ad hoc announcement
|Company:||IGEA Pharma N.V.|
|2123 WT Hoofddorp|
|Phone:||+31 23 568 9494|
|Listed:||Regulated Unofficial Market in Frankfurt; SIX Swiss Exchange|
|EQS News ID:||1252110|
|End of Announcement||EQS Group News Service|
GBC im Fokus
IGEA Pharma N.V. Realignment to CBD extraction
The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.
Der AKTIONÄR News
03. Dezember 16:37 Allianz: Kursziel 250 Euro
03. Dezember 16:48 Update DocuSign: Minus steigt auf 40 Prozent! Der nächste ...
03. Dezember 17:00 DAX: Der nächste Nackenschlag
03. Dezember 17:54 Börsenpunk: DAX - Angst ist zurück an den Märkten - jetzt trotzdem ...
03. Dezember 18:09 Alibaba, Tencent und Co: Kleiner Crash vorm Wochenende
News im Fokus
Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an
03. Dezember 2021, 07:03
FY 2020/2021 Financial Results
16. Dezember 2021
Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen
02. Dezember 2021